The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

The present disclosure provides methods for controlling the rate of ripening for agricultural produce. The present disclosure further provides coating compositions that can be applied to produce to control (e.g., lessen) the rate of ripening of the produce.

The present disclosure provides methods for controlling the rate of ripening for agricultural produce. The present disclosure further provides coating compositions that can be applied to produce to control (e.g., lessen) the rate of ripening of the produce.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I,

##STR00001##

wherein X is CO or CH.sub.2; Y is NH, O or absent; R is a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T=1224 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoid environmental oxidation and increase the environmental stability of drugs containing the compounds.

Provided herein are methods of making capsinoids including providing a capsiate synthase in a mixture or cellular system, feeding 8-methyl-6-nonenoyl-CoA, 6E-8-methylnonenoic acid or 8-methylnonanoic acid into the mixture or cellular system, feeding vanillyl alcohol into the mixture or cellular system, and collecting capsinoids from the mixture or cellular system.

Provided herein are methods of making capsinoids including providing a capsiate synthase in a mixture or cellular system, feeding 8-methyl-6-nonenoyl-CoA, 6E-8-methylnonenoic acid or 8-methylnonanoic acid into the mixture or cellular system, feeding vanillyl alcohol into the mixture or cellular system, and collecting capsinoids from the mixture or cellular system.

The disclosure relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma. The disclosure also relates to methods of treating conditions using prodrugs of vitamin K2.